Celldex Therapeutics, Inc. 8-K

What Happened
Celldex Therapeutics, Inc. announced its financial results for the first quarter of 2026 in a press release dated May 7, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K (Accession No. 0001171843-26-003153) filed the same day under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 7, 2026 (Form 8-K, Accession No. 0001171843-26-003153).
• Event: Press release announcing Q1 2026 financial results, furnished as Exhibit 99.1 and incorporated by reference.
• SEC items reported: Item 2.02 (results of operations) and Item 9.01 (exhibits — Exhibit 99.1 and Inline XBRL cover page).
• The filing furnishes the earnings/quarterly results disclosure; the press release itself contains the detailed financial figures (see Exhibit 99.1).

Why It Matters
This 8-K signals Celldex has publicly released its Q1 2026 earnings and operational results — key information investors use to evaluate recent performance and outlook. Retail investors should read the May 7 press release (Exhibit 99.1) for the specific revenue, net income/loss, cash position, and management commentary. The Form 8‑K does not report executive changes, mergers, or other corporate actions beyond the quarterly results disclosure.